Target

Our most advanced program, NGM282 is an engineered variant of the human hormone fibroblast growth factor 19, or FGF19, which we are developing as a once-daily injection for the treatment of NASH.

FGF19 is a highly specific and potent regulator of liver fat metabolism and bile acid synthesis that we believe is responsible for some of the beneficial effects of gastric bypass surgery on NASH.

Data

Preliminary results from Phase 2 clinical trials have provided clinical proof of concept of NGM282 by demonstrating statistically significant reductions in liver fat, liver transaminases and biomarkers of fibrosis, which has translated to improvements in liver histology and fibrosis at 12 weeks.

Anticipated Upcoming Milestone

We plan to begin a Phase 2b dose range-finding clinical trial of NGM282 for the treatment of NASH patients with F2 or F3 liver fibrosis in the first quarter of 2019.

Target

NGM313 is an agonistic antibody binding to fibroblast growth factor receptor 1c-beta-klotho, or FGFR1c/KLB, which regulates insulin sensitivity, blood glucose and liver fat. NGM313, being developed as a once-monthly injection, has the potential to be a best-in-class insulin sensitizer for the treatment of type 2 diabetes (T2D) and NASH. NGM313 works by selectively activating the FGFR1c/KLB co-receptor complex, which regulates energy expenditure and glucose uptake in fat cells and other tissues.

Data

Preliminary data from a Phase 1b early proof-of-concept clinical trial in obese insulin resistant subjects with nonalcoholic fatty liver disease, or NAFLD, demonstrated that a single dose of NGM313 resulted in a statistically significant reduction in liver fat content and improvements in multiple metabolic parameters.

Anticipated Upcoming Milestone

We expect to receive additional Phase 1b data in the fourth quarter of 2018.

Target

NGM120 is a long-acting antagonistic antibody binding glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, that is designed to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome, or CACS, and possibly, cancer.

NGM120 works by selectively inhibiting the interaction between GDF15 and its cognate receptor GFRAL, through which the autonomic nervous system and, possibly, the neuroendocrine axis influence the body’s fuel flux to propel uncontrolled weight loss associated with many types of cancer and, possibly, cancer itself, in cancer patients who have high serum levels of GDF15.

Upcoming Anticipated Milestone

We are currently testing NGM120 in healthy volunteers in a Phase 1 clinical trial to assess its safety, tolerability and pharmacokinetic profile.

We expect to initiate a Phase 1b clinical trial of NGM120 in cancer patients with CACS in the first half of 2019.

NGM217 is a long-acting antibody binding an undisclosed target, designed to restore pancreatic islet function and increase insulin production in patients with diabetes.

NGM217 is in a Phase 1 clinical trial where we are assessing its safety and tolerability profile in adults with diabetes.

NGM621 is a long-acting antibody binding an undisclosed target, designed to decrease levels of a protein implicated in the dry form of age-related macular degeneration, or dry AMD.

NGM621 is in IND-enabling studies, and we expect to begin a Phase 1 safety, tolerability and pharmacokinetics clinical trial in patients with geographic atrophy, or GA, an advanced form of dry AMD, in the second half of 2019.

NGM386 is an engineered variant of the human hormone known as growth differentiation factor 15, or GDF15, which we are developing with Merck for the treatment of obesity.

GDF15 drives profound metabolic activity by regulating fuel flux and has been considered a challenging therapeutic target.

We discovered that metabolic activity of GDF15 is mediated by glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, which is located in a region of the brain stem outside of the blood-brain barrier.

NGM386, being developed as a once-daily injection, is designed to stimulate a pathway that modulates the autonomic nervous system and, possibly, the neuroendocrine axis to modify body weight and fat levels in the body.

NGM395 is an engineered long-acting variant of the human hormone known as growth differentiation factor 15, or GDF15, which we are developing with Merck for the treatment of obesity.

GDF15 drives profound metabolic activity by regulating fuel flux and has been considered a challenging therapeutic target.

We discovered that metabolic activity of GDF15 is mediated by glial cell-derived neurotrophic factor receptor alpha-like, or GFRAL, which is located in a region of the brain stem outside of the blood-brain barrier.

NGM395, being developed as a once-weekly or less frequent injection, is designed to stimulate a pathway that modulates the autonomic nervous system and, possibly, the neuroendocrine axis to modify body weight and fat levels in the body.